YD Bio Ltd
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| YDES | OCUL | EYPT | SRZN | CUVL | OCS | |
|---|---|---|---|---|---|---|
| Market cap | 448.36M | 1.66B | 278.35M | 291.02M | 281.92M | 485.31M |
| P/E (TTM) | — | — | — | — | 12.4 | — |
| Forward P/E | — | -5.1 | -1.2 | -5.9 | — | -4.1 |
| Price/book | 100.5 | 3.2 | 1.7 | -1.3 | 1.5 | 1.9 |
| Dividend yield | — | — | — | — | 0.64% | — |
| 1-year change | −65.79% | −32.68% | −74.77% | +81.52% | −31.20% | −63.42% |
| Today | −5.94% | +0.27% | −2.35% | −16.60% | +0.43% | −5.52% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All YDES news ›YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment
For individuals whose Assessment indicates a denser cluster of risk factors associated with certain cancer types, the report may reference the availability of related blood tests for discussion with a physician. Whether any test is…
Price to book forward of YD Bio Limited – NASDAQ:YDESW – TradingView
YD Bio Ltd. is a biotechnology company building an integrated healthcare platform across regulated diagnostics, clinical services, and commercial healthcare markets. It operates DNA methylation–based oncology testing programs under an…
YD Bio (NASDAQ:YDES) Stock Price Down 4.4% – Should You Sell?
Posted by Sarita Garza on Sep 30th, 2026 Shares of YD Bio Limited (NASDAQ:YDES – Get Free Report) dropped 4.4% during trading on Wednesday. The company traded as low as $6.80 and last traded at $7.2760. 68,234 shares traded hands during…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
stocktitan.net1
-
themarketsdaily.com1
-
tradingview.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.